Quick Answer
FDA conducts routine and for-cause inspections of registered facilities. Being prepared is not optional — it is the difference between a clean inspection and a warning letter. This playbook walks you through every phase: pre-inspection preparation, documentation readiness, employee training, on-site conduct, 483 response strategy, and post-inspection follow-up.
Regulatory Authority
FDA inspection authority is established under Section 704 of the Federal Food, Drug, and Cosmetic Act (FD&C Act). Inspection procedures are detailed in the FDA Investigations Operations Manual (IOM), the agency's primary reference for conducting field operations. The IOM covers investigator conduct, evidence collection, sampling, and enforcement recommendations.
Understanding FDA Inspection Types
Not all FDA inspections are the same. Understanding the type of inspection your facility faces helps you allocate preparation resources effectively. The four primary inspection categories differ in trigger, scope, and consequence.
| Inspection Type | Trigger | Frequency | Scope | Duration |
|---|---|---|---|---|
| Routine / Surveillance | Scheduled based on risk profile and statutory mandate | Every 2–5 years (varies by industry) | Comprehensive review of systems, records, and facility conditions | 3–10 business days |
| For-Cause | Complaint, adverse event report, recall, or import violation | Any time; unannounced | Focused on the specific issue that triggered the inspection | 1–5 business days |
| Pre-Approval (PAI) | Pending NDA, ANDA, BLA, or PMA submission | Once per submission (drugs/devices) | Verifies data integrity and manufacturing capability for the specific product | 1–3 weeks |
| Compliance Follow-Up | Prior 483 observations, warning letter, or consent decree | Within 6–18 months of prior action | Verifies corrective actions from prior inspection have been implemented | 2–5 business days |
Under FSMA, FDA is mandated to inspect domestic high-risk food facilities at least once every three years and all other domestic food facilities at least once every five years. Drug manufacturing facilities registered under 21 CFR Part 207 are typically inspected on a two-year cycle, though resource constraints can extend this interval.
Pre-Inspection Preparation Checklist
Inspection readiness is a continuous discipline, not a last-minute scramble. The following checklist covers the operational, documentation, and personnel actions you should maintain at all times so your facility is ready when an FDA investigator presents credentials at your door.
Inspection Readiness Checklist
Critical Mistake: Waiting Until FDA Arrives
The most common and costliest mistake is treating inspection readiness as a project rather than a program. Facilities that begin preparation only after learning of an upcoming inspection almost always have gaps that result in 483 observations. Readiness should be validated continuously through internal audits and mock inspections.
Facility and Documentation Readiness
FDA investigators evaluate your physical facility and your documentation systems in parallel. A spotless facility with poor records is just as problematic as a well-documented facility with sanitation failures. Both dimensions must be maintained simultaneously.
Document Categories to Have Inspection-Ready
Standard Operating Procedures
All SOPs must be current, approved, version-controlled, and accessible to the employees who execute them. FDA investigators routinely compare the SOP on file with actual practice on the production floor.
Batch and Production Records
Complete batch records for at least the past 3 years, including in-process checks, yield calculations, deviations, and release decisions. Records must be legible, contemporaneous, and attributable.
Training Records
Documented evidence that every employee performing regulated activities has been trained on applicable SOPs and cGMP/HACCP/QSR requirements. Include training dates, trainer credentials, and competency assessments.
CAPA and Deviation Logs
All corrective and preventive action records with root cause analyses, timelines, effectiveness checks, and closure documentation. Open CAPAs should have documented target dates and assigned owners.
Complaint and Adverse Event Files
Every customer complaint related to product quality or safety, with investigation records, trending analysis, and any required adverse event reports submitted to FDA (MedWatch, FAERS, etc.).
Validation and Qualification Records
Equipment qualification (IQ/OQ/PQ), process validation, cleaning validation, and method validation protocols and reports. Ensure revalidation is performed on schedule.
Facility Condition Essentials
- Sanitation and housekeeping: Production areas, storage rooms, and common areas must be clean and orderly. FDA investigators note visible contamination risks, pest evidence, and general facility condition in their reports.
- Equipment labeling: All equipment should be clearly labeled with status (clean, dirty, in use, out of service) and calibration status. Expired calibration stickers are a common 483 observation.
- Material segregation: Raw materials, in-process materials, finished goods, rejected materials, and returned goods must be physically separated and clearly identified.
- Temperature and environmental controls: Verify that temperature-controlled areas are within specification and that monitoring data is being recorded continuously.
Keep your inspection documents organized and accessible
Assurentry's Audit Vault centralizes SOPs, batch records, training logs, and CAPA files in one inspection-ready system.
Start My RegistrationEmployee Training for FDA Inspections
Your employees are the front line during an FDA inspection. An untrained employee who volunteers information, speculates about root causes, or contradicts an SOP can create observations that would not otherwise exist. Conversely, well-trained employees who understand their role during an inspection project competence and instill investigator confidence.
Employee Inspection Training: Dos and Don'ts
Train Employees To:
- Answer questions truthfully, briefly, and only about their specific job responsibilities
- Refer questions outside their scope to the designated inspection escort
- Know their SOPs and be able to describe the procedures they actually perform
- Understand that the investigator has a legal right to be on premises
- Remain calm and professional regardless of the question asked
- Notify the inspection lead immediately if the investigator requests a document or observation
- Continue performing their normal duties correctly while being observed
Train Employees NOT To:
- Volunteer information that was not asked for
- Speculate about why something happened or what might be wrong
- Argue with the investigator or become defensive
- Provide documents without first clearing it with the inspection lead
- Discuss ongoing investigations, lawsuits, or internal disputes
- Alter, hide, or destroy any document or record
- Use informal language like 'we always do it this way' if it contradicts the SOP
Conduct at least one mock inspection per year where a member of your QA team or an external consultant role-plays as an FDA investigator. This exercise surfaces training gaps and builds employee confidence before the real event.
During the Inspection: Dos and Don'ts
When an FDA investigator presents their credentials (Form FDA 482, Notice of Inspection), the inspection has officially begun. How you conduct yourself during the inspection directly influences the outcome. The goal is to be cooperative, organized, and transparent without giving the investigator reasons to expand the scope of the inspection.
Do:
- Verify the investigator's credentials (Form FDA 482) and photocopy them
- Assign a dedicated escort who accompanies the investigator at all times
- Take detailed notes of every question asked, document requested, and area visited
- Provide a clean, private conference room for the investigator to review records
- Supply requested documents promptly; photocopy everything you provide
- Correct any observed issues immediately where possible (e.g., a hand-washing violation)
- Request a daily debrief with the investigator to understand emerging concerns
- Have your quality and regulatory team available on-site throughout the inspection
- Photograph or record (with permission) any conditions the investigator observes
- Ask the investigator to clarify any observation you do not fully understand
Don't:
- Delay or obstruct the investigator's access to any area or record
- Provide documents beyond what was specifically requested
- Allow employees to be interviewed without the escort present
- Make promises about corrective actions without management approval
- Argue about regulatory interpretation during the inspection
- Attempt to influence, intimidate, or bribe the investigator
- Destroy, alter, or conceal any document or record (this is a federal offense)
- Allow the investigator to wander the facility unescorted
- Discuss the inspection on social media or with unauthorized parties
- Sign the Form 483 under pressure without reading it carefully
Important: The Close-Out Meeting
At the end of the inspection, the investigator will conduct a close-out meeting where they present any Form 483 observations. This is your opportunity to discuss each observation, ask clarifying questions, and provide any immediate corrections or context. Do not sign the 483 without reading every observation carefully. Your signature acknowledges receipt, not agreement.
Responding to FDA 483 Observations
While there is no legal requirement to respond to a Form 483, failing to do so significantly increases the likelihood that the observations will escalate to a warning letter. FDA expects a written response within 15 business days of the close-out meeting. A well-crafted 483 response demonstrates that your company takes compliance seriously and is actively correcting the identified deficiencies.
483 Response Framework
1. Acknowledge Each Observation
Address every observation individually, in the same order as listed on the 483. Do not skip or combine observations. Acknowledge the finding even if you plan to provide context or disagreement.
2. Describe the Root Cause Investigation
Explain the methodology used to investigate the root cause (e.g., fishbone diagram, 5 Whys, fault tree analysis). Identify the systemic root cause, not just the immediate symptom.
3. Detail Immediate Corrective Actions
List every corrective action already taken, with specific dates. Include evidence: revised SOPs (with document numbers and revision dates), retraining records, equipment repairs, product holds, or disposition decisions.
4. Outline Preventive Actions and Timelines
Describe systemic changes to prevent recurrence across the operation, not just fixes for the specific instance cited. Provide specific target completion dates and responsible individuals for each action.
5. Include Supporting Documentation
Attach copies of revised SOPs, training records, CAPA forms, test results, validation protocols, or photographs that support your response. Tangible evidence is far more persuasive than narrative promises.
What to Avoid in Your 483 Response
- Vague language such as 'we will improve our procedures' without specifics
- Blaming individual employees rather than identifying systemic failures
- Disputing observations without providing documented evidence
- Missing the 15-business-day deadline (even a partial response is better than none)
- Promising corrective actions with no realistic completion dates
- Ignoring observations you disagree with instead of addressing them with evidence
For a deeper look at the escalation path from 483 observations to formal enforcement, see our FDA Warning Letter Response Guide.
Post-Inspection Follow-Up
The inspection does not end when the investigator leaves your facility. Post-inspection follow-up is critical for closing out observations, preventing escalation, and strengthening your compliance program for future inspections.
Post-Inspection Timeline
| Timeframe | Action | Owner |
|---|---|---|
| Day 0 (Close-Out) | Receive Form 483, debrief internally with inspection team, notify senior management and legal | Inspection Lead |
| Days 1–3 | Launch root cause investigations for each observation; assign CAPA owners; begin immediate corrective actions | QA Director |
| Days 4–10 | Draft 483 response with corrective actions, evidence, and target dates; internal review by quality, regulatory, and legal | Regulatory Affairs |
| Days 11–15 | Finalize and submit 483 response to the district office; retain copies of all submitted materials | Regulatory Affairs |
| 30–90 Days | Complete remaining corrective actions per committed timelines; send follow-up correspondence with evidence of completion | CAPA Owners |
| 6–12 Months | Verify effectiveness of all CAPAs; conduct internal audit focused on prior 483 observations; prepare for potential follow-up inspection | QA Director |
Best Practice: Proactive Follow-Up
Even after submitting your 483 response, continue sending follow-up letters to the district office as you complete each committed corrective action. This demonstrates sustained commitment to compliance and creates a documented record that is favorable if a follow-up inspection occurs.
Industry-Specific Inspection Focus Areas
FDA inspection priorities and evaluation criteria vary significantly by the type of facility being inspected. The following cards summarize the primary regulatory framework and common focus areas for each major industry category.
Food Manufacturing (cGMP / FSMA)
21 CFR Part 117 • FSMA Preventive Controls
- • Hazard analysis and preventive controls plan
- • Supplier verification under FSVP
- • Sanitation and allergen controls
- • Environmental monitoring for pathogens (Listeria, Salmonella)
- • Recall plan and traceability records (FSMA 204)
- • Preventive Controls Qualified Individual (PCQI) training
Drug Manufacturing (cGMP)
21 CFR Parts 210/211 • ICH Q7/Q10
- • Process validation and continued process verification
- • Laboratory controls and data integrity (ALCOA+ principles)
- • Equipment cleaning validation and changeover procedures
- • Stability testing programs and expiration dating
- • Complaint handling and adverse event reporting (FAERS)
- • Annual Product Reviews (APR) / Product Quality Reviews
Medical Devices (QSR / QMSR)
21 CFR Part 820 • ISO 13485 Alignment
- • Design controls and design history file (DHF)
- • Risk management per ISO 14971
- • Device master record (DMR) and device history record (DHR)
- • MDR (Medical Device Reporting) compliance
- • UDI labeling and GUDID submissions
- • Supplier controls and purchasing procedures
Cosmetics (MoCRA)
MoCRA • 21 CFR Parts 700–740
- • Facility registration and product listing compliance
- • Good manufacturing practice for cosmetics
- • Safety substantiation documentation
- • Adverse event reporting (serious adverse events within 15 days)
- • Fragrance allergen labeling (effective 2026)
- • Records maintenance and availability
For food facilities specifically, review our cGMP Food Manufacturing Guide for a detailed breakdown of current Good Manufacturing Practice requirements. You can also use our Compliance Calculator to determine which regulations apply to your specific product type and facility.
Not sure which regulations apply to your facility?
Use our free Compliance Calculator to identify your specific FDA obligations in minutes.
Try Compliance CalculatorHow Assurentry's Audit Vault Helps
Assurentry's Audit Vault is purpose-built for FDA inspection readiness. It provides a centralized, always-accessible document management system designed around the specific records FDA investigators request during inspections.
Centralized Document Repository
All SOPs, batch records, training logs, CAPA files, complaint records, and validation documents in a single, searchable system. No more scrambling through filing cabinets or shared drives during an inspection.
Version Control and Audit Trails
Every document change is tracked with timestamps, user attribution, and version history. This satisfies FDA's expectations for document control under 21 CFR Part 11 and cGMP requirements.
Inspection-Ready Organization
Documents are organized by the categories FDA investigators request: SOPs, batch records, training, CAPAs, complaints, validation, and supplier qualifications. Pull up any record in seconds during a live inspection.
Automated Reminders and Alerts
Receive alerts for expiring training certifications, overdue CAPA items, upcoming calibration due dates, and registration renewal deadlines so nothing falls through the cracks.
Mock Inspection Reports
Generate inspection readiness scorecards that evaluate your document completeness against FDA inspection criteria. Identify gaps before the investigator does.
Whether you are preparing for a routine surveillance inspection or responding to a for-cause investigation, Assurentry gives your team the tools to respond quickly and demonstrate compliance. Explore our full service catalog or contact our compliance team for a readiness assessment.
Frequently Asked Questions
How often does the FDA inspect registered facilities?
FDA inspection frequency varies by industry and risk level. High-risk food facilities are inspected every 3 years under FSMA. Drug and device manufacturers are typically inspected every 2 years. For-cause inspections can occur at any time based on complaints, adverse events, or import violations.
Can I refuse an FDA inspection?
Technically you can refuse entry, but refusal to permit inspection is a prohibited act under Section 301(f) of the FD&C Act. It can result in a warning letter, import alerts, injunction, or criminal prosecution. In practice, refusing an inspection triggers more aggressive enforcement than cooperating.
What is the difference between a Form 483 and a warning letter?
A Form 483 lists observations noted during an inspection and is issued at the close of the inspection. A warning letter is a formal enforcement communication issued after FDA headquarters reviews the inspection report and determines significant violations require correction. Not all 483s lead to warning letters.
How long does a typical FDA inspection last?
Routine surveillance inspections typically last 3 to 10 business days. Pre-approval inspections can last 1 to 3 weeks. For-cause inspections may be shorter but more focused. Complex cGMP inspections at large pharmaceutical sites can extend to 4 weeks or more.
Do I have to provide documents immediately during an inspection?
You are expected to provide records in a timely manner, but FDA understands that some records take time to locate. It is acceptable to commit to providing a document by a specific time. Unreasonable delays, however, may be noted as obstruction or evidence of inadequate document management.
Can I have legal counsel present during an FDA inspection?
Yes, you have the right to have legal counsel present. However, the investigation should not be delayed while waiting for an attorney. Many companies notify counsel immediately and have them join as soon as possible, either remotely or in person.
What should I do if I disagree with a 483 observation?
You should still respond professionally and completely. In your written response, respectfully explain why you believe the observation is incorrect, providing supporting evidence such as SOPs, test results, or regulatory citations. Ignoring an observation is far riskier than addressing it with a documented counterargument.
Does Assurentry help with FDA inspection preparation?
Yes. Assurentry's Audit Vault provides a centralized, inspection-ready document repository that organizes SOPs, batch records, training logs, CAPA files, and complaint records. We also offer mock inspection services and 483 response drafting assistance.
Stop reading. Start executing.
Assurentry acts as a technical translation layer. You provide basic business info, and we automatically generate and file the exact electronic submissions required by the FDA.
Automate compliance100% FDA Acceptance Guaranteed